The switching reportWhy long-time NAD+ users are drifting toward urolithin A
Both are sold as cellular energy supplements. Their human evidence bases are built very differently, and buyers are starting to notice.
Home / The switching report
What is moving
The switching report
Every few months a compound moves from niche to mainstream, or from mainstream to quietly discontinued. We track those movements and then go and read the human evidence behind them, including the studies that found nothing.
Articles
4
Covers
Mitophagy and autophagy compounds
Covers
NAD+ precursors
Covers
Senolytics
All the switching report
Newest first. Every piece lists its sources at the foot.
The switching report
The switching reportFisetin's dose problem is quietly reshaping how it is sold
The senolytic story is built on mouse data and a handful of human trials. The bigger obstacle for buyers is that most capsules cannot deliver a meaningful dose.
The switching reportSpermidine is outselling its evidence, and one trial may change that
A dietary polyamine with a strong mechanistic case, good observational data, and almost no confirmatory human trial results. A cardiology trial should report soon.
The switching reportThe GLP-1 era rewrote the supplement shelf
Prescription weight-loss drugs changed what people want from a supplement. The industry responded with a wave of products making adjacent claims.